On June 10, 2026, stockholders approved an amendment to the Company's 2023 Equity Incentive Plan, increasing the number of reserved shares of Common Stock for issuance by 3,500,000. Other annual meeting results included the election of nine directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026, and the non-binding advisory approval of named executive officer compensation. Veracyte operates in the healthcare industry, developing genomic diagnostics to inform patient management.
